Immunogen (NASDAQ: IMGN) Surge on News of Takeover by AbbVie
AbbVie (NYSE:ABBV) announced Thursday that it will acquire Immunogen (IMGN) and its flagship cancer therapy, Elahere, in a deal worth $31.26 per share.
The transaction values ImmunoGen (NASDAQ:IMGN) at a total equity value of approximately $10.1 billion and is expected to close in the middle of 2024.
Elahere is considered a "first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC)." ABBV believes the deal accelerates its commercial and clinical presence in the solid tumor space.
"The acquisition of ImmunoGen demonstrates our commitment to deliver on our long-term growth strategy and enables AbbVie to further diversify our oncology pipeline across solid tumors and hematologic malignancies," said Richard Gonzalez, chairman and chief executive officer of AbbVie. "Together, AbbVie and ImmunoGen have the potential to transform the standard of care for people living with cancer."
ImmunoGen shares have rocketed 83% to over $29 per share on the news.
"We see the deal as a positive for biotech as it reflects our view that quality oncology assets are of high interest to large pharma and merit a premium".
Price Momentum
IMGN is trading near the top of its 52-week range and above its 200-day simple moving average.
What does this mean?
Investors have been pushing the share price higher, and the stock still appears to have upward momentum. This is a positive sign for the stock's future value.
The transaction values ImmunoGen (NASDAQ:IMGN) at a total equity value of approximately $10.1 billion and is expected to close in the middle of 2024.
Elahere is considered a "first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC)." ABBV believes the deal accelerates its commercial and clinical presence in the solid tumor space.
"The acquisition of ImmunoGen demonstrates our commitment to deliver on our long-term growth strategy and enables AbbVie to further diversify our oncology pipeline across solid tumors and hematologic malignancies," said Richard Gonzalez, chairman and chief executive officer of AbbVie. "Together, AbbVie and ImmunoGen have the potential to transform the standard of care for people living with cancer."
ImmunoGen shares have rocketed 83% to over $29 per share on the news.
"We see the deal as a positive for biotech as it reflects our view that quality oncology assets are of high interest to large pharma and merit a premium".
Price Momentum
IMGN is trading near the top of its 52-week range and above its 200-day simple moving average.
What does this mean?
Investors have been pushing the share price higher, and the stock still appears to have upward momentum. This is a positive sign for the stock's future value.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.